GlassScriptPhysician profile
Marga B Ngwang
NPI 1861703654
$4,303.27
in general payments reported to CMS, 2019-2025
46 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $386 · 2021: $757 · 2022: $774 · 2023: $551 · 2024: $696 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $452.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $378.06 | 2021-2024 | Farxiga, Lokelma, Airsupra |
| Otsuka America Pharmaceutical, INC. | $346.20 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $286.95 | 2021-2024 | Veozah, Myrbetriq |
| Ucb, INC. | $204.95 | 2021-2024 | Briviact |
| Lundbeck LLC | $198.08 | 2024-2025 | Rexulti |
| Cmp Pharma, INC. | $179.74 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $179.32 | 2020-2021 | |
| Lilly USA, LLC | $170.41 | 2020-2025 | Mounjaro, Kisunla, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $152.57 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $150.96 | 2019-2020 | |
| Urovant Sciences INC | $147.28 | 2021-2022 | |
| Abbvie INC. | $121.82 | 2020-2023 | |
| Novo Nordisk INC | $112.18 | 2019-2020 | |
| Pfizer INC. | $111.92 | 2019-2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marga Ngwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.